Global Glioblastoma Multiforme Therapeutics Market Growth 2023-2029

Global Glioblastoma Multiforme Therapeutics Market Growth 2023-2029

Glioblastoma multiforme is the most aggressive variant of malignant brain cancer. It has a poor prognosis with low rate of survival, a median of one year. The primary brain tumor happens due to uncontrolled cell division and developments in the brain. The tumors can be found in the glial cells or the neuron. The one which develops in the glial cells (astrocytes and oligodendrocytes) is called glioma, the commonest forms of brain tumor.

LPI (LP Information)' newest research report, the “Glioblastoma Multiforme Therapeutics Industry Forecast” looks at past sales and reviews total world Glioblastoma Multiforme Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Glioblastoma Multiforme Therapeutics sales for 2023 through 2029. With Glioblastoma Multiforme Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glioblastoma Multiforme Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Glioblastoma Multiforme Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glioblastoma Multiforme Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glioblastoma Multiforme Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glioblastoma Multiforme Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glioblastoma Multiforme Therapeutics.

The global Glioblastoma Multiforme Therapeutics market size is projected to grow from US$ 536.3 million in 2022 to US$ 985.3 million in 2029; it is expected to grow at a CAGR of 985.3 from 2023 to 2029.

Currently unavailable therapies and prognosis for the treatment of GBM is expected to impact the market growth positively through to 2022. Presence of the treatment options which do not increase the overall survival rate in patients such as surgical resection, which is followed by chemotherapy and radiotherapy, is another factor attributing towards the expected growth of this market. Moreover, the fact that glioma stem cells resist conventional treatments also raises urgent need for alternative treatment therapies for glioblastoma multiforme thus driving the market. Increasing R&D in gene therapy and molecular biotechnology for the treatment of CNS associated disorders and cancer is anticipated to fuel the market growth over the forecast period. However, high expenditure involved in research employing genomics based research is a key restraint for market.

This report presents a comprehensive overview, market shares, and growth opportunities of Glioblastoma Multiforme Therapeutics market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Temozolomide
Bevacozumab
Carmustine

Segmentation by application
Hospitals
Clinics
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Arbor Pharmaceuticals
Bristol-Myers Squibb
Eisai
F. Hoffmann-La Roche
Merck

Key Questions Addressed in this Report

What is the 10-year outlook for the global Glioblastoma Multiforme Therapeutics market?

What factors are driving Glioblastoma Multiforme Therapeutics market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Glioblastoma Multiforme Therapeutics market opportunities vary by end market size?

How does Glioblastoma Multiforme Therapeutics break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.